Abstract
By 2015, the biomarker market is forecast to be worth over US$20 billion as
the cardiovascular and CNS biomarker market segments begin to mature with the
launch of a number of diagnostic tests to guide the treatment of
neuropsychiatric and neurodegenerative diseases.
This new 3-volume report provides a comprehensive analysis of the major
therapy areas which are driving growth, along with a critical assessment of
the companies involved.
Unique analysis and scoring
To provide commercial and industry managers with qualified insight to the
corporate landscape, the report provides a unique assessment and scoring
system for each company covering:
- Biomarker technology
- Association/clinical studies
- Management strategy
- Application & potential
View Cart
